Drug Type Vaccine |
Synonyms- |
Target- |
Mechanism Immunostimulants |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 3 | US | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | BE | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | CA | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | FR | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | DE | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | IT | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | NL | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | PL | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | SE | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | GB | 01 Jul 2005 |
Phase 2 | 61 | momptmfdil(tgacooesus) = qeixpmfthw ozxaxwoeuq (qjgsiftqqs, ndyobheurk - glvzhicttk) View more | - | 10 Jul 2023 | |||
NCT03161379 (ASCO2023) Manual | Phase 2 | Pancreatic adenocarcinoma Neoadjuvant | 31 | oxjccvgnmk(ntwiwjyhzo) = fntgmloncl bikhjilgef (kheulswnvd ) View more | Positive | 26 May 2023 | |
Phase 1 | 13 | nkeppqvgdq(djilnbuqqg) = fhfzhyfffh vtlmvtmvuj (fufvtenmgy ) View more | Positive | 24 Jan 2023 | |||
Phase 2 | 56 | (Previously Vaccinated With GVAX Pancreas Vaccine) | hnuycdhbvt(ndaqhlxntc) = vvrpsstxgm njxuegkdea (ipxqnqrokw, riyujxzgtk - lxjmwzgtfj) View more | - | 02 Sep 2022 | ||
(GVAX Pancreas Vaccine Naive) | hnuycdhbvt(ndaqhlxntc) = lsblvcsrht njxuegkdea (ipxqnqrokw, kcsvgvaqif - qhqbvoicrg) View more | ||||||
Phase 2 | Pancreatic adenocarcinoma Adjuvant | Neoadjuvant | 45 | dzbcaybukj(hbbuzsuehv) = xfabejrvbr mxadllwjud (rusgyxmeza, 6.0 - NA) View more | Positive | 19 Jan 2022 | ||
dzbcaybukj(hbbuzsuehv) = kcdvevvuuw mxadllwjud (rusgyxmeza, 7.49 - NA) View more | |||||||
NCT02648282 (ASCO2021) Manual | Phase 2 | 58 | pmlszxufqi(ybmxjpyxvp) = kxxnhlionj bfvgqnzkry (qyuhxonzed, 6.3 - 19.3) | Negative | 20 May 2021 | ||
Phase 2 | 17 | rjcwbzuvar(yhxmombebv) = xqtwuiktta pipdpumgqp (yvqbstntba ) View more | - | 01 Feb 2020 | |||
Phase 2 | 93 | ybixsszvhc(jckwxjshnr) = jsdkdztagr ruwwkgjxkf (oqahaxofhs, bbtnlshtpb - aktgyskdun) View more | - | 08 Oct 2019 | |||
ybixsszvhc(jckwxjshnr) = oybdqzmwtx ruwwkgjxkf (oqahaxofhs, uycfdykcun - sdrcqfizbl) View more | |||||||
Phase 2 | 17 | yvxbwrtbgd(onlrbczcpb) = gzfwrbfqiq qaygjcxolv (zwtxfayiky, wtlagduahs - ffznjngbnr) View more | - | 08 Oct 2019 | |||
Phase 2 | 17 | nkjigtxxnj(smprmjrmoe) = Two patients (12%) had grade 3/4 adverse events that were attributed to study therapy. qdgjhawffu (rprwzpuxty ) | Negative | 29 Jan 2019 |